SLC22A3 and prostate carcinoma: Furthermore, OCT3 has a low expression in prostate cancer lines and higher expression levels of OCT3 have been associated with cancer suppressive effects, possibly due to the enhanced transcription rate and higher expression caused by the rs555754 and rs60515630 polymorphisms [75].